Amberstone Biosciences discovers novel immunotherapies.
Our focus is difficult targets requiring a unique mode-of-action and/or particular functional property, which are otherwise challenging for traditional approaches.
These conventional limitations are overcome via a two-pronged approach. First, we have demonstrated success with our microfluidics-powered AmberFlow drug-discovery platform. Second, our team of experts have keen insights in immuno-oncology and ample experience with single-cell assay biology.
By leveraging this unique combination of assets, we are developing intramural antibody programs and advancing our biopharmaceutical partners’ immunotherapy pipelines.
We welcome additional synergistic alliances to discover next-generation therapeutic biologics where these key internal Amberstone resources are of strategic advantage and mutually beneficial for our collaborators.